Dr. Craig Granowitz
Analyst
Equibles does not estimate personal net worth.
About Dr. Craig Granowitz
Dr. Craig Granowitz has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Lexicon Pharmaceuticals, Inc. on September 14, 2026. The companies whose calls Dr. Craig Granowitz spoke on are classified in the Healthcare sector.
Dr. Craig Granowitz on recent calls
“And I think that is really the most important point is that the disease historically has been defined by the treatment options for surgery. and now what I would call a negative ionotrope that reduces the contractility of the heart.”
“The FDA has previously confirmed that Steno1, an open-label investigator-initiated study of sodoglifosin being conducted by the StenoDiabetes Center in Denmark, may serve as that prospective study.”
“I'll start with sodaglifosin, our novel oral SGLT1 and SGLT2 inhibitor, which is in late-stage development in both HCM and type 1 diabetes. I want to take a moment and remind everyone of the important and unique effects of sodaglifosin's mechanism of action.”
“As most of you know, our pipeline is focused in two primary therapy areas, the first being cardiometabolic disease and the second being chronic pain. I'll start with our cardiometabolic platform and sodalifocin.”